跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,441 条关于
“DE-DLBCL”
全部
6,441
临床试验
3,552
药物
354
机构
945
资讯
1,590
去年
CCL2/CCR2 Pathway Identified as Key Driver of Aggression in Double-Expressor DLBCL
去年
Knight Therapeutics Launches Minjuvi for Relapsed/Refractory DLBCL in Mexico
5个月前
PRMT5 Inhibition Sensitizes B-Cell Lymphoma to Ferroptosis via ATF5-SLC7A11 Axis
2年前
Bristol Myers Squibb Initiates Two Phase I Trials Testing Novel Therapies for Advanced Solid Tumors and Relapsed/Refractory Lymphomas
去年
FS118, a LAG-3/PD-L1 Bispecific Antibody, Shows Modest Efficacy in Relapsed/Refractory DLBCL
去年
Delayed Treatment May Improve Outcomes for Older DLBCL Patients, Study Suggests
去年
FDA Advisory Committee Discusses Columvi Combination for Relapsed or Refractory DLBCL
6年前
FDA Approves Monjuvi in Combination with Lenalidomide for Relapsed/Refractory DLBCL
去年
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
去年
Odronextamab Shows Manageable Safety Profile in DLBCL Patients Post-CAR T-cell Therapy
第 1 页,共 159 页
上一页
下一页